Is LSD toxic?
This study (2018) re-examined five cases of fatality described by media as related to LSD toxicity, and found that none of those cases were actually attributable to physiological LSD toxicity.
Authors
- David Nichols
- Charles Grob
Published
Abstract
LSD (lysergic acid diethylamide) was discovered almost 75 years ago, and has been the object of episodic controversy since then. While initially explored as an adjunctive psychiatric treatment, its recreational use by the general public has persisted and on occasion has been associated with adverse outcomes, particularly when the drug is taken under suboptimal conditions. LSD’s potential to cause psychological disturbance (bad trips) has been long understood, and has rarely been associated with accidental deaths and suicide. From a physiological perspective, however, LSD is known to be non-toxic and medically safe when taken at standard dosages (50-200 μg). The scientific literature, along with recent media reports, have unfortunately implicated “LSD toxicity” in five cases of sudden death. On close examination, however, two of these fatalities were associated with ingestion of massive overdoses, two were evidently in individuals with psychological agitation after taking standard doses of LSD who were then placed in maximal physical restraint positions (hogtied) by police, following which they suffered fatal cardiovascular collapse, and one case of extreme hyperthermia leading to death that was likely caused by a drug substituted for LSD with strong effects on central nervous system temperature regulation (e.g. 25i-NBOMe). Given the renewed interest in the therapeutic potential of LSD and other psychedelic drugs, it is important that an accurate understanding be established of the true causes of such fatalities that had been erroneously attributed to LSD toxicity, including massive overdoses, excessive physical restraints, and psychoactive drugs other than LSD.
Research Summary of 'Is LSD toxic?'
Introduction
Nichols and colleagues situate LSD (lysergic acid diethylamide) as a semi-synthetic compound derived from ergot that was first synthesised in 1938 and discovered to be psychoactive in 1943. Early clinical work from the 1950s–1960s encompassed roughly 40,000 treated subjects and about 1,000 case reports, with comprehensive reviews from that era reporting low rates of adverse effects. The passage of the Controlled Substances Act in 1970 halted FDA‑approved LSD studies in the United States, although recent controlled studies have resumed in Europe. The paper addresses a persistent public and medico-legal question: is LSD physiologically toxic at standard recreational or investigational doses (commonly discussed in the paper as 50–200 units, noting extraction inconsistencies in unit reporting)? Nichols and colleagues aim to clarify reported fatalities allegedly due to LSD by reviewing case reports, pharmacokinetic data, and forensic findings, and to distinguish deaths plausibly caused by LSD itself from those resulting from massive overdoses, positional/physical restraint, or other psychoactive compounds substituted for LSD. The authors argue this clarification is important given renewed clinical interest in psychedelic therapies.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Authors
- APA Citation
Nichols, D. E., & Grob, C. S. (2018). Is LSD toxic?. Forensic Science International, 284, 141-145. https://doi.org/10.1016/j.forsciint.2018.01.006
References (18)
Papers cited by this study that are also in Blossom
Cohen, S. · Journal of Nervous and Mental Disease (1980)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Liechti, M. E., Dolder, P. C., Grünblatt, E. et al. · Frontiers in Pharmacology (2017)
Strajhar, P., Schmid, Y., Liakoni, E. et al. · Journal of Neuroendocrinology (2016)
Liechti, M. E. · Neuropsychopharmacology (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Show all 18 referencesShow fewer
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Dolder, P. C., Schmid, Y., Haschke, M. et al. · International Journal of Neuropsychopharmacology (2015)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Kirchner, K. · Journal of Psychopharmacology (2014)
Cited By (4)
Papers in Blossom that reference this study
Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L. et al. · Neuropharmacology (2026)
Henríquez-Hernández, L. A., Rojas-Hernández, J., Quintana-Hernández, D. J. et al. · Toxics (2023)
Mellner, C., Dahlen, M., Simonsson, O. · International Journal of Environmental Research and Public Health (2022)
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.